Literature DB >> 7561031

Ig domains 1 and 2 of murine CD22 constitute the ligand-binding domain and bind multiple sialylated ligands expressed on B and T cells.

C L Law1, A Aruffo, K A Chandran, R T Doty, E A Clark.   

Abstract

Baby hamster kidney cells transfected with murine CD22 (mCD22) mediate adhesion to B- and T-lineage cells. To further characterize mCD22-mediated cell adhesion, we generated a panel of recombinant globulins (Rg) consisting of different extracellular Ig-like (Ig) domains of mCD22. FACS analysis using these mCD22.Rgs revealed that ligands for mCD22 are expressed on both B and T cell lines and also normal B and T cells. In B-lineage cells, the expression of mCD22 ligands began on sIgM- pre-B cells in bone marrow. The ligand-binding site of mCD22 for ligands was mapped to Ig domains 1 and 2: mCD22.Rgs containing Ig domains 1 and 2 bound target cells and immunoprecipitated sets of glycoproteins similar to Rgs containing Ig domains 1 to 3 or all 7 CD22 Ig domains, whereas Rgs containing Ig domains 2 to 3 or 3 to 7 did not bind either B or T cells. Furthermore, B cells apparently expressed higher levels of mCD22 ligands than that of T cells, suggesting a potential competition for CD22 binding between ligands expressed on the same B cell and those expressed on another B cell or T cells. Immunoprecipitation experiments using the mCD22.Rgs identified mCD22 itself and the B cell-specific isoform of mCD45RA (B220) as two of the mCD22 ligands expressed on B cells. Thus, mCD22 may potentially regulate B cell activation through interactions with itself or mCD45RA/B220.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561031

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

Review 1.  Siglecs in the immune system.

Authors:  P R Crocker; A Varki
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

2.  Characterization of CD22 expression in acute lymphoblastic leukemia.

Authors:  Nirali N Shah; Maryalice Stetler Stevenson; Constance M Yuan; Kelly Richards; Cindy Delbrook; Robert J Kreitman; Ira Pastan; Alan S Wayne
Journal:  Pediatr Blood Cancer       Date:  2015-03-01       Impact factor: 3.167

3.  CD22 expression mediates the regulatory functions of peritoneal B-1a cells during the remission phase of contact hypersensitivity reactions.

Authors:  Hiroko Nakashima; Yasuhito Hamaguchi; Rei Watanabe; Nobuko Ishiura; Yoshihiro Kuwano; Hitoshi Okochi; Yoshimasa Takahashi; Kunihiko Tamaki; Shinichi Sato; Thomas F Tedder; Manabu Fujimoto
Journal:  J Immunol       Date:  2010-03-24       Impact factor: 5.422

4.  Dendritic cell-dependent inhibition of B cell proliferation requires CD22.

Authors:  Lorna Santos; Kevin E Draves; Mark Boton; Prabhjit K Grewal; Jamey D Marth; Edward A Clark
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

5.  Cell surface GPI-anchoring of CD45 isoforms.

Authors:  G B ten Dam; L G Poels; B Wieringa
Journal:  Mol Biol Rep       Date:  1998-11       Impact factor: 2.316

6.  In situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics.

Authors:  T N C Ramya; Eranthie Weerapana; Lujian Liao; Ying Zeng; Hiroaki Tateno; Liang Liao; John R Yates; Benjamin F Cravatt; James C Paulson
Journal:  Mol Cell Proteomics       Date:  2010-02-19       Impact factor: 5.911

7.  A novel subset of murine B cells that expresses unmasked forms of CD22 is enriched in the bone marrow: implications for B-cell homing to the bone marrow.

Authors:  H Floyd; L Nitschke; P R Crocker
Journal:  Immunology       Date:  2000-11       Impact factor: 7.397

Review 8.  The potential role of sialoadhesin as a macrophage recognition molecule in health and disease.

Authors:  P R Crocker; A Hartnell; J Munday; D Nath
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

9.  Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact.

Authors:  Brian E Collins; Ola Blixt; Alexis R DeSieno; Nicolai Bovin; Jamey D Marth; James C Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

10.  Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts.

Authors:  Robert T O'Donnell; Yunpeng Ma; Hayes C McKnight; David Pearson; Joseph M Tuscano
Journal:  Cancer Immunol Immunother       Date:  2009-05-13       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.